katie8288Jun 250 min readWave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave received supportive initial feedback from FDA on WVE-003. FDA also granted WVE-003 Orphan Drug Designation.
Comments